Active Wound Care Market 2019 - Power of Active Wound Care Healing Lies in Managing Wounds on Time and with Proper Care

Active wound care management not only protects the wound, but heals it at a faster rate. In 2014, a U.S. based regenerative medicine company called Tissue Regenix introduced its dermal substitute product - DermaPure HD. This product is based on a dCELL technology, a patented regenerative medicine technology by Tissue Regenix. In 2019, the company collaborated with Group Purchasing Organization (GPO) for the further use of DermaPure HD to treat chronic and active wounds. The company is further focusing on the development of various wound healing technologies and active wound care products to effectively enhance healing caused by chronic diseseses or trauma. Such innovations are likely to augur well for the Global Active Wound Care Market.

Fortune Business Insights in predicts the active wound are market to grow significantly throughout the forecast period. In 2017, the active wound care market was valued at US$ 1361.7 Mn and is projected to reach US$ 2039.9 Mn by the end of 2025. If these figures hold true, the market is expected to witness a CAGR of 5.3% between 2018 and 2025.

Growth Opportunities in Active Wound Care Market Encourages Innovation in Healthcare Sector

Researchers estimate that around 1 to 2% of population, especially in developed countries may experience a chronic or active wound during their lifespan. These numbers are likely to increase owing to the drastic rise in geriatric population because wound closure is difficult to manage at this age. Active wounds in such patients include infections such as lower-extremity amputations, eczema, and cellulitis. Scientists are developing a high standard of active wound care products to speed up the healing process in aging people. In addition to this, pharmacists are constantly updating their skills to take better care of their geriatric patients. The above mentioned initiatives are expected to shape the active wound care market in a better way.

According to the Centers for Diseases Control and Prevention (CDC), 2 out of every 5 Americans are likely to develop type 2 diabetes during their lifetime. Another study conducted by the National Institute of Health (NIH) states that the prevalence of type 2 diabetes is projected to increase by 54% from a population of over 54.9 million from 2015 to 2030. Diabetic foot ulcer is the major complication associated with diabetes.  It is estimated that the number of patients suffering from diabetic foot ulcers in the U.S. will increase in the coming years. As a result, there is a higher risk of tissue damage in these patients owing to weakening health caused by diabetes. The high incidence of diabetic foot ulcers will subsequently increase the demand for various wound care treatment products, enabling growth in the active wound care market. . Some of the treatments include dead tissue removal from the wound, blood sugar control, and active wound dressings.

Moreover, the University of South Australia is training students on how to improve the high-risk foot conditions caused by diabetes. Recently, the university developed a creative method by using 3D printed feet combined with gooey mixture such as chicken stock and icing sugar. The aim is to train students on how to remove dead skin tissues from patient’s foot suffering from diabetes and encourage healing. All the above mentioned factors can drive the active wound care market and encourage innovative in the healthcare industry.

Innovative Active Wound Care Products to Greatly Impact the Active Wound Care Market

The wound care technology is evolving rapidly with an aim to reduce the overall duration and cost of the active wound care treatment. As a result, an emerging trend towards implementing more cost-effective programs in active wound care treatment across several healthcare centers is introduced.

In 2018, Mölnlycke acquired another company called SastoMed GmbH to expand its product portfolio by introducing two innovative products. These products, called Granulox and Granudacyn, will help the company to stay ahead of competition in active wound care treatments. Another company called Ilya Pharma designed a new technology for chronic wounds in 2018. This drug delivery is created to heal active wounds faster and accelerate the whole process of healing. Many other companies are also focusing on developing innovative products and technologies to heal chronic wounds on time.